The case for investing in the prevention and control of non-communicable diseases in the six countries of the Gulf Cooperation Council: an economic evaluation

Khalifa Elmusharaf*, Daniel Grafton, Johanna S. Jung, Emily Roberts, Yahya Al-Farsi, Ameera Ali Al Nooh, Buthaina Bin Belaila, Amin Elshamy, Hamoud Al-Zuabi, Kholood Ateeq Al Mutawa, Shadha Alraisi, Najla Al Lawat, Ali Gharbal, Shaker Alomary, Alexey Kulikov, Nasim Pourghazian, Slim Slama, Dudley Tarlton, Nicholas Banatvala

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background While the non-communicable disease (NCD) burden in the countries of the Gulf Cooperation Council (GCC) (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates) has surged over the past decades, the costs and return on investment (ROI) of implementing cost-effective, WHO-recommended NCD interventions have not been established. Methods We performed an economic analysis to estimate the ROI from scaling up four sets of NCD interventions over 15 years. We estimated the direct costs of the four main NCDs (cancer, diabetes, cardiovascular diseases and chronic respiratory diseases) using a prevalence-based, bottom-up cost-of-illness approach. We estimated indirect costs based on productivity loss due to absenteeism, presenteeism and premature deaths. We costed the scaling up of interventions using the WHO Costing Tool and assessed the health impact of interventions using the OneHealth Tool. We calculated ROI by comparing productivity and social benefits with the total costs of implementing the interventions. Results The four main NCDs cost the GCC economy nearly US$50 billion in 2019, equal to 3.3% of its gross domestic product. The indirect costs are estimated at US$20 billion or 40% of the total burden. Implementing the four modelled intervention packages in the six GCC countries over 15 years will cost US$14 billion, with an ROI of US$4.9 for every US$1 invested and significant health and social benefits, including 290 000 averted premature deaths. Conclusion Based on the results of these six investment cases, we recommend actions to scale up current WHO-recommended cost-effective interventions, strengthen whole-of-government action, drive the NCD legislative agenda, build out the evidence base, generate additional advocacy material, and increase regional collaboration and data-sharing to establish best practices and monitor impact.

Original languageEnglish
Article numbere008670
JournalBMJ Global Health
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 2 2022

Keywords

  • Cancer
  • Cardiovascular disease
  • Diabetes
  • Health economics
  • Prevention strategies

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this